Eli Lilly and Company (NYSE: LLY) announced a definitive agreement to acquire Ajax Therapeutics, a biopharmaceutical company developing JAK inhibitors ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions